高级检索
当前位置: 首页 > 详情页

The effects of estimated glucose disposal rate and high sensitivity C-reactive protein on risk of incident cardiovascular diseases in middle-aged and elderly Chinese adults: a nationwide prospective cohort study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Southwest Med Univ, Affiliated Hosp, Dept Endocrinol & Metab, Luzhou 646000, Sichuan, Peoples R China [2]Sichuan Clin Res Ctr Nephropathy, Luzhou 646000, Sichuan, Peoples R China [3]Metab Vasc Dis Key Lab Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China [4]Sichuan Chongqing Joint Key Lab Metab Vasc Dis, Luzhou 646000, Sichuan, Peoples R China [5]Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Neurol, Shanghai 200336, Peoples R China
出处:
ISSN:

关键词: Cardiovascular diseases Estimated glucose disposal rate High sensitivity C-reactive protein Cohort studies China

摘要:
AimCardiovascular diseases (CVD) remain the predominant contributor to global mortality and morbidity, necessitating enhanced strategies for primary prevention and early detection. This investigation sought to characterize the associations between estimated glucose disposal rate (eGDR), high sensitivity C-reactive protein (hsCRP), and incident CVD.MethodsThe research used data from China Health and Retirement Longitudinal Study (CHARLS). The primary exposures included eGDR and hsCRP. Incident CVD served as the primary study endpoint. All statistical analyses were performed utilizing SPSS software (version 25.0) and R software (version 4.4.4).ResultsThe analysis of 7,742 participants revealed incident CVD in 1,981 cases (25.6%), with Kaplan-Meier curves demonstrating significantly elevated cumulative incidence among individuals exhibiting both reduced eGDR and elevated hsCRP levels. Significant interactions were observed between these biomarkers, including an additive effect (relative excess risk due to interaction = 0.09, 95% confidence interval [CI]: 0.03-0.14) and a multiplicative effect (hazard ratio = 1.02, 95% CI: 1.01-1.03). Mediation analyses indicated bidirectional relationships, with eGDR accounting for 5.81% (95% CI: 2.13-9.49%) of the hsCRP-CVD association and hsCRP mediating 8.52% (95% CI: 3.87-13.17%) of the eGDR-CVD relationship. Notably, in individuals with diabetes, the combined predictive capacity of eGDR and hsCRP (area under the curve: 0.645) demonstrated superior discriminative performance compared to either biomarker alone (AUC: 0.645).ConclusioneGDR and hsCRP exert significant joint, interactive and mediating effects on incident CVD in middle-aged and elderly Chinese population. Using eGDR (10.52 mg/kg/min) and hsCRP (1 mg/L) thresholds can be an affordable screening tool in primary care, especially where advanced diagnostics are lacking. Incorporating these assessments into regular check-ups may lower long-term CVD complications and reduce economic burdens.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 生化与分子生物学 2 区 营养学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 生化与分子生物学 2 区 营养学
JCR分区:
出版当年[2023]版:
Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 NUTRITION & DIETETICS
最新[2024]版:
Q1 NUTRITION & DIETETICS Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Southwest Med Univ, Affiliated Hosp, Dept Endocrinol & Metab, Luzhou 646000, Sichuan, Peoples R China [2]Sichuan Clin Res Ctr Nephropathy, Luzhou 646000, Sichuan, Peoples R China [3]Metab Vasc Dis Key Lab Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China [4]Sichuan Chongqing Joint Key Lab Metab Vasc Dis, Luzhou 646000, Sichuan, Peoples R China
通讯作者:
通讯机构: [1]Southwest Med Univ, Affiliated Hosp, Dept Endocrinol & Metab, Luzhou 646000, Sichuan, Peoples R China [2]Sichuan Clin Res Ctr Nephropathy, Luzhou 646000, Sichuan, Peoples R China [3]Metab Vasc Dis Key Lab Sichuan Prov, Luzhou 646000, Sichuan, Peoples R China [4]Sichuan Chongqing Joint Key Lab Metab Vasc Dis, Luzhou 646000, Sichuan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:28954 今日访问量:0 总访问量:1618 更新日期:2025-10-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)